Savara (SVRA) Accumulated Expenses (2010 - 2026)
Savara (SVRA) posted quarterly Accumulated Expenses of $11.0 million for Q1 2026, up 979.47% year-over-year from $1.0 million in Q1 2025, and down 24.56% quarter-over-quarter from $14.6 million in Q4 2025.
Savara (SVRA) Accumulated Expenses (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Accumulated Expenses for 17 consecutive years, with $11.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 979.47% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $11.0 million (up 979.47% YoY), while the FY2025 annual figure was $14.6 million, up 191.79% from the prior year.
- Accumulated Expenses slipped to $11.0 million in Q1 2026 per SVRA's latest filing, from $14.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $14.6 million in Q4 2025 and bottomed at $590000.0 in Q1 2022.
- Historically, Accumulated Expenses has averaged $4.3 million across 5 years, with a median of $2.9 million in 2022.
- Annual changes were most pronounced in 2025 — Accumulated Expenses sank 71.41% — and 2026, when it jumped 979.47%.
- Savara's Accumulated Expenses stood at $2.4 million in 2022, then soared by 199.92% to $7.1 million in 2023, then declined by 29.27% to $5.0 million in 2024, then soared by 191.79% to $14.6 million in 2025, then retreated by 24.56% to $11.0 million in 2026.
- Business Quant data shows SVRA's Accumulated Expenses at $11.0 million in Q1 2026, $14.6 million in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.60 Mn |
| Mar 31, 2026 | 11.04 Mn |
| Dec 31, 2025 | 14.64 Mn |
| Sep 30, 2025 | 3.92 Mn |
| Jun 30, 2025 | 2.26 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 2.84 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 757,000.00 |
| Dec 31, 2023 | 7.09 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 3.38 Mn |
| Mar 31, 2023 | 603,000.00 |
| Dec 31, 2022 | 2.37 Mn |
| Sep 30, 2022 | 4.27 Mn |
| Jun 30, 2022 | 2.90 Mn |
| Mar 31, 2022 | 590,000.00 |
| Dec 31, 2021 | 4.88 Mn |
| Sep 30, 2021 | 5.22 Mn |